Shares of Hologic HOLX were unchanged in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 19.05% over the past year to $0.75, which beat the estimate of $0.37.
Revenue of $822,900,000 decreased by 3.46% year over year, which beat the estimate of $607,710,000.
Outlook
Q4 EPS expected between $0.95 and $1.15.
Q4 revenue expected between $925,000,000 and $1,025,000,000.
Details Of The Call
Date: Jul 29, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/e9eoejo2
Technicals
Company's 52-week high was at $63.60
52-week low: $26.49
Price action over last quarter: Up 38.70%
Company Profile
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: breast health (44% of sales), diagnostics (39%) surgical (14%), and skeletal health (3%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%), Asia (9%), and other international markets (5%). Hologic is headquartered in Bedford, Massachusetts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.